Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.

Article Details

Citation

Copy to clipboard

Young RM, Lawford BR, Barnes M, Burton SC, Ritchie T, Ward WK, Noble EP

Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.

Br J Psychiatry. 2004 Aug;185:147-51.

PubMed ID

15286066 [ View in PubMed

]

Abstract

BACKGROUND: Hyperprolactinaemia induced by D(2) dopamine receptor antagonist antipsychotic medication can result in significant health problems. AIMS: To examine the role of DRD2 polymorphism on prolactin levels in patients treated with antipsychotic medication. METHOD: Antipsychotic drugs with different degrees of D(2) receptor binding were given to 144 patients with schizophrenia. Serum prolactin levels were obtained and Taq1A DRD2 alleles were determined. RESULTS: Prolactin levels increased across medication groups reflecting increasingly tight D(2) receptor binding (clozapine, olanzapine, typical antipsychotics and risperidone). In the combined medication group, patients with the DRD2(*)A1allele had 40% higher prolactin levels than patients without this allele. In patients treated with clozapine (the loosest D(2) receptor binding agent), patients with the DRD2(*)A1allele had prolactin levels twice those of patients without this allele. CONCLUSIONS: Patients with the DRD2A1 allele receiving antipsychotic medications had higher prolactin levels and were overrepresented among those with hyperprolactinaemia, suggesting greater functional D(2) receptor binding in this group.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Clozapine	Dopamine D2 receptor	Protein	Humans	Yes	Antagonist	Details